CING may be getting ready CING is resting on 50 EMA, and on a key level.
It is also flashing 'bottom in' on CM WilliamsVixFix indicator and it has a healthy RSI.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−85.79 USD
−23.53 M USD
0.00 USD
2.05 M
About Cingulate Inc.
Sector
CEO
Shane J. Schaffer
Headquarters
Kansas City
Website
Founded
2013
FIGI
BBG012G40MY2
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
$CING Cingulate Inc Target PT 33 and higherNASDAQ:CING Cingulate Inc
Target PT 33 and higher
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), whi
$CING - Cingulate ADHD 1 Dose Medicine, MICRO FLOAT, ROCKET SHIP937K shares, 2.2M marketcap micro float. ADHD 1 dose medicine advancing through trials with FDA guidance. I wouldn't be surprised to see NASDAQ:ARCT , NASDAQ:DRRX , or NASDAQ:NLSP buy them up! Do your own due diligence. Do not take this as financial advice. I own shares in this company.
$CING - LOW FLOAT + CAP - 1 Pill for ADHD/ANXIETY (ROCKETSHIP?)They announced positive top line results from their P3 trial. Adolescent and paediatric trials are happening both this month and next. Major competitors such as NYSE:JNJ , NYSE:PFE , NYSE:NVS that require multiple pills a day for the same effect. Extremely large TAM. Buyout candidate? We have po
$CING - Low Float - Positive Top Line Results - ADHD 1 PILLWe are traveling the bottom of the channel. I think it starts to move up shortly. Adolescent and Pediatric fixed dose phase 3 trials start this month and next month. FDA approval submission early/mid next year. Billion-dollar drug if it can get some funding? This is my own opinion, and you should no
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CING is 3.47 USD — it has increased by 2.38% in the past 24 hours. Watch Cingulate Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cingulate Inc. stocks are traded under the ticker CING.
CING stock has fallen by −17.70% compared to the previous week, the month change is a −29.22% fall, over the last year Cingulate Inc. has showed a −96.10% decrease.
We've gathered analysts' opinions on Cingulate Inc. future price: according to them, CING price has a max estimate of 75.00 USD and a min estimate of 70.00 USD. Watch CING chart and read a more detailed Cingulate Inc. stock forecast: see what analysts think of Cingulate Inc. and suggest that you do with its stocks.
CING reached its all-time high on Dec 8, 2021 with the price of 1,236.00 USD, and its all-time low was 1.80 USD and was reached on Aug 14, 2024. View more price dynamics on CING chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CING stock is 6.38% volatile and has beta coefficient of 17.70. Track Cingulate Inc. stock price on the chart and check out the list of the most volatile stocks — is Cingulate Inc. there?
Today Cingulate Inc. has the market capitalization of 7.50 M, it has decreased by −7.99% over the last week.
Yes, you can track Cingulate Inc. financials in yearly and quarterly reports right on TradingView.
Cingulate Inc. is going to release the next earnings report on Mar 7, 2025. Keep track of upcoming events with our Earnings Calendar.
CING earnings for the last quarter are −1.83 USD per share, whereas the estimation was −2.36 USD resulting in a 22.57% surprise. The estimated earnings for the next quarter are −2.36 USD per share. See more details about Cingulate Inc. earnings.
Cingulate Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CING net income for the last quarter is −3.23 M USD, while the quarter before that showed −3.21 M USD of net income which accounts for −0.68% change. Track more Cingulate Inc. financial stats to get the full picture.
No, CING doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 13.00 employees. See our rating of the largest employees — is Cingulate Inc. on this list?
Like other stocks, CING shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cingulate Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cingulate Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cingulate Inc. stock shows the sell signal. See more of Cingulate Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.